142 related articles for article (PubMed ID: 7518092)
1. Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.
Wikstrand CJ; Fredman P; Svennerholm L; Bigner DD
Prog Brain Res; 1994; 101():213-23. PubMed ID: 7518092
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.
Wikstrand CJ; He XM; Fuller GN; Bigner SH; Fredman P; Svennerholm L; Bigner DD
J Neuropathol Exp Neurol; 1991 Nov; 50(6):756-69. PubMed ID: 1748882
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to malignant human gliomas.
Wikstrand CJ; Fredman P; Svennerholm L; Humphrey PA; Bigner SH; Bigner DD
Mol Chem Neuropathol; 1992 Oct; 17(2):137-46. PubMed ID: 1384525
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.
Wikstrand CJ; Fredman P; McLendon RR; Svennerholm L; Bigner DD
Mol Chem Neuropathol; 1994; 21(2-3):129-38. PubMed ID: 7522005
[TBL] [Abstract][Full Text] [Related]
5. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.
Wikstrand CJ; Longee DC; McLendon RE; Fuller GN; Friedman HS; Fredman P; Svennerholm L; Bigner DD
Cancer Res; 1993 Jan; 53(1):120-6. PubMed ID: 8416736
[TBL] [Abstract][Full Text] [Related]
6. Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
Piao H; Kuan CT; Chandramohan V; Keir ST; Pegram CN; Bao X; Månsson JE; Pastan IH; Bigner DD
MAbs; 2013; 5(5):748-62. PubMed ID: 23924792
[TBL] [Abstract][Full Text] [Related]
7. The presence of foetal ganglioside antigens 3'-isoLM1 and 3'6'-isoLD1 in both glioma tissue and surrounding areas from human brain.
von Holst H; Nygren C; Boström K; Collins VP; Fredman P
Acta Neurochir (Wien); 1997; 139(2):141-5. PubMed ID: 9088372
[TBL] [Abstract][Full Text] [Related]
8. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.
Kato Y; Kuan CT; Chang J; Kaneko MK; Ayriss J; Piao H; Chandramohan V; Pegram C; McLendon RE; Fredman P; Månsson JE; Bigner DD
Biochem Biophys Res Commun; 2010 Jan; 391(1):750-5. PubMed ID: 19944071
[TBL] [Abstract][Full Text] [Related]
9. The glioma-associated gangliosides 3'-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains.
Hedberg KM; Mahesparan R; Read TA; Tysnes BB; Thorsen F; Visted T; Bjerkvig R; Fredman P
Neuropathol Appl Neurobiol; 2001 Dec; 27(6):451-64. PubMed ID: 11903928
[TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.
Longee DC; Wikstrand CJ; Månsson JE; He X; Fuller GN; Bigner SH; Fredman P; Svennerholm L; Bigner DD
Acta Neuropathol; 1991; 82(1):45-54. PubMed ID: 1659106
[TBL] [Abstract][Full Text] [Related]
11. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
[TBL] [Abstract][Full Text] [Related]
12. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
13. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.
Bernhard H; Roth S; Bauerschmitz J; Meyer zum Büschenfelde KH; Dippold W
Int J Cancer; 1992 Jun; 51(4):568-72. PubMed ID: 1376299
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro.
Hedberg KM; Dellheden B; Wikstrand CJ; Fredman P
Glycoconj J; 2000 Oct; 17(10):717-26. PubMed ID: 11425192
[TBL] [Abstract][Full Text] [Related]
15. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
16. Expression of GD2-epitopes in human intracranial tumors and normal brain.
Mennel HD; Bosslet K; Wiegandt H; Sedlacek HH; Bauer BL; Rodden AF
Exp Toxicol Pathol; 1992 Oct; 44(6):317-24. PubMed ID: 1280497
[TBL] [Abstract][Full Text] [Related]
17. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
Dippold W; Bernhard H
Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
[TBL] [Abstract][Full Text] [Related]
18. Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors.
Fredman P
Prog Brain Res; 1994; 101():225-40. PubMed ID: 8029453
[TBL] [Abstract][Full Text] [Related]
19. GD3 expression by cultured human tumor cells of neuroectodermal origin.
He X; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
Acta Neuropathol; 1989; 79(3):317-25. PubMed ID: 2609939
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors.
Mennel HD; Bosslet K; Geissel H; Bauer BL
Exp Toxicol Pathol; 2000 Aug; 52(4):277-85. PubMed ID: 10987178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
